have evolved
Harnessing more of the immune system for better cancer outcomes
Latest News

Fascinating discovery led by Michael Chopin @WEHI_research
Differential role of PRC2 complex in myeloid cell development. Michael is emerging as a national leader in myeloid/DC research. Very exciting area 👏

@Daily_Experts Blood Cancer Awareness Month. Our @MonashBDI lab and @oNKo_innate are working hard on understanding NK cell biology to reveal drug targets to boost NK cell immunity to blood cancers. Tumour engager biologics and CAR cell therapies are having a BIG impact but still lots to do.....

We’re delighted to receive $16.12 million through the State Government’s Victorian Higher Education State Investment Fund to enhance smart manufacturing, and #research and development commercialisation at Monash. 🧑‍🔬 Learn more:

Load More...
Discover oNKo-innate
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to master NK cell biology and therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
Learn more
Using powerful genomic approaches, we screen primary immune cells and cancer cells to understand their interaction within a tumor.
Learn more
o o
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
Find out who we are